EGFR-TKI治疗晚期非小细胞肺癌的临床疗效和安全性观察  

The clinical efficacy and tolerability of EGFR-TKI in locally advanced or metastatic NSCLC patients

作　　者：葛小琴[1,2] 袁瑛[1] 沈虹[1] 

机构地区：[1]浙江大学医学院附属第二医院肿瘤科,杭州310009 [2]在宁波市第一医院血液肿瘤科

出　　处：《浙江医学》2010年第7期1028-1030,共3页Zhejiang Medical Journal

摘　　要：目的 评价表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）对局部晚期或转移性非小细胞肺癌（NSCLC）患者临床疗效与安全性.方法 对经病理确诊的初治或经治的29例晚期NSCLC的患者,予吉非替尼250mg/d或厄洛替尼150mg/d 口服,至肿瘤进展或发生不可耐受的毒副作用.结果 29例患者的总有效率为48.3%,疾病控制率为72.4%,中位疾病进展时间为7.7个月;随访结束时11例患者死亡,死亡患者的中位生存期为8个月;主要的的毒副作用是皮疹和腹泻,均可耐受.结论 EGFR-TKI制剂治疗NSCLC,具有较好的疗效和耐受性.Objective Gefitinib and erlotinib are small molecule tyrosine kinase inhibitors of the epidermal growth factor receptor （EGFR-TKI）. EGFR-TKI is a valid treatment for advanced non-small-cell lung cancer （NSCLC）. Increased likelihood of responding to small-molecule therapy is associated with Asian race, female gender, never smoking and adenocarcinoma. To evaluate the clinical efficacy and toterability of EGFR-TKI in locally advanced or metastatic NSCLC patients. Methods Twenty-nine pathologically verified, locally advanced or metastatic NSCLC patients were treated with gefitinib 250 mg/d or erlotinib 150mg/d, until disease progression or unacceptable toxicity. Results Overall response rate （RR） of 29 patients was 48.3%, and the disease control rate （DCR） was 72.4%. The median progession-free survival （PFS） was 7.7 month. At the end of follow-up, eleven patients died of lung cancer. The median overall survival of these dead patients was 8 months. The most common drug-related adverse events were skin rashes and diarrhea, but generally mild and tolerant. Conclusion EGFR-TKI is effective and safe in the treatment of patients with locally advanced or metastatic NSCLC

关 键 词：非小细胞肺癌 EGFR—TKI 吉非替尼 厄洛替尼 

分 类 号：R512.5[医药卫生—内科学]